20.5 C
New York
Thursday, June 18, 2026

Tag: intellectual property

XORTX Completes USD $114,500 Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Dorel Reports Second Quarter 2025 Results

MONTRÉAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) today announced its financial results for the second quarter and six months ended June 30, 2025.

Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions

MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- MIAMI, FL – August 8, 2025 – Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced its financial and operational results for the first fiscal quarter ended June 30, 2025.

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

Company to host an investor conference call and webcast at 4:30 pm ET
Company to host an investor conference call and webcast at 4:30 pm ET

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron announces the pricing of a public offering of common stock and warrants.

REPEAT – Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).

Saks Global Announces Early Settlement of the Exchange Offer and Consent Solicitation, Completing Previously Announced $600 Million Financing Package

Company received $300 million in connection with the Exchange Offer on August 8, 2025 Holders of approximately 98% of the aggregate principal amount of the...

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

KOPPERS REPORTS SECOND QUARTER 2025 RESULTS; REVISES 2025 OUTLOOK

Sales of $504.8 Million vs. $563.2 Million in Prior Year QuarterNet income attributable to Koppers of $16.4 Million vs. $26.8 Million in Prior Year...

THE WENDY’S COMPANY REPORTS SECOND QUARTER 2025 RESULTS

Global systemwide sales were $3.7 billion, a decrease of 1.8%International systemwide sales grew 8.7% with growth across all regionsAdded 26 net new restaurants and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsIntellectual property